BioVoice News April 2017 Issue 11 Volume 1 | Page 13

reintroduce the bill, the opposition party too must support. And if I remember correctly, Mr Shashi Tharoor had supported it earlier but with few amendments. We as an industry association have pressed to DBT for making it a reality. I sincerely wish it comes through. How do you look at the regulatory issues especially in case of clinical trials? Hope can we change the situation? The global companies had put lot of investments into their CRO work, drug discovery, early stage discovery etc. We completely drove them away with our facts and figures on clinical trial deaths. We knee jerked badly to any episode. Either we didn’t put enough checks and balances or we simply lost the plot. Today this industry is global. If they didn’t get the environment here, they left for other better destinations. We cold shoulder everybody who wants to come here for investments through our acts. I am not simply blaming government but all of us, the stakeholders. Time has come to pull our efforts in sync with each other to come out of this situation and present India again as a right destination. Many people tell me that while BIRAC has been doing a good job, we require more BIRACs. Do you agree? All the new emerging areas can contribute tremendously in overall growth of the biotech sector. It is ultimately what the PM Modi said: ‘The more you do the business, economy develops and so does the sector on its own’ It is self-fueling. BIOVOICENEWS.COM 13